Arq. Bras. Oftalmol. 2026;89 (1 )
:1-4
| DOI: 10.5935/0004-2749.2024-0402
Abstract
PURPOSE: This study evaluated the proportion of corneas discarded by the Eye Bank of Londrina, Paraná, due to positive serology over a 5-year period and its impact on transplant availability.
METHODS: A cross-sectional study was conducted, analyzing 1,968 corneas from 1,056 donors collected between January 2014 and December 2018 at the Eye Bank of Londrina. Serological tests for hepatitis B (HBsAg and anti-HBc), hepatitis C (anti-HCV), and HIV (anti-HIV 1 and 2) were performed using chemiluminescent microparticle immunoassays. Data were analyzed descriptively and presented in tables and graphs.
RESULTS: Of the 1,968 corneas processed, 897 (45.57%) were discarded. Among these, 333 (37.12%) tested positive for serological markers. Hepatitis B accounted for 34.67% of positive cases (15% of total donations), hepatitis C for 1.11% (0.50% of total), and HIV for 0.89% (0.4% of total). Hepatitis cases remained stable between 2014 and 2016, with a marked decline in 2017 and 2018. Most discarded corneas were positive for anti-HBc (31.88%) and negative for HBsAg; however, the anti-HBs test was not performed to confirm immunity to the hepatitis B virus.
CONCLUSION: The findings highlight the importance of serological testing to identify and eliminate contaminated corneas, thereby preventing the transmission of infectious diseases to recipients. Positive serology for hepatitis, particularly hepatitis B, was the leading cause of corneal disposal.
Keywords: Cornea; Corneal transplantation; Corneal donation; Eye banks; Hepatitis B virus; Hepatitis C virus; HIV infections; Seropositivity; Serologic tests
Arq. Bras. Oftalmol. 2025;88 (3 )
:1-6
| DOI: 10.5935/0004-2749.2024-0207
Abstract
PURPOSE: This study aimed to report the use, efficacy, and safety of intracameral voriconazole as an adjuvant treatment for deep fungal keratitis.
METHODS: This was a prospective case series of seven eyes with fungal keratitis with anterior chamber involvement or a corneal ulcer refractory to conventional topical treatment. In addition to topical treatment with 0.15% amphotericin B eye drops, voriconazole 50 μg/ 0.1 mL
was administered to the anterior chamber of each affected eye up to four times within 72 h. The primary outcome measures were healing (fungal eradication) and the need for therapeutic keratoplasty. Best-corrected visual acuity was a secondary outcome measure.
RESULTS: Three cases were confirmed by confocal microscopy, and four were diagnosed from positive culture tests. At presentation, one patient had a best-corrected visual acuity of 20/80, while all others had hand motion or worse. Four cases received one intracameral injection, two cases received three, and one case received four injections. There were no complications after any of the intracameral voriconazole injections. Four patients had imminent corneal perforations and were treated with cyanoacrylate adhesive and bandage contact lenses. Four patients recovered from the infection, and three underwent therapeutic keratoplasty. The final best-corrected visual acuity was improved in two cases but all patients had a final visual acuity of counting fingers or worse.
CONCLUSION: As an adjuvant treatment for deep fungal keratitis, intracameral voriconazole injection is a feasible option. Although fungal eradication was achieved in all patients, three required therapeutic keratoplasty and all patients had unsatisfactory visual acuity outcomes.
Keywords: Antifungal agents; Fungi; Corneal transplantation; Keratitis; Eye infections, fungal; Voriconazole